{"analyses":[{"ciLowerLimit":"1.07","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"16.90","groupDescription":"Stratified Analysis: The stratification factors were ECOGPS at randomization (0 vs. 1);LDH at randomization (\\<=ULN vs \\>ULN) via local laboratory test; Presence of liver metastases at enrollment (yes vs. no); Prior receipt of PCI (yes vs. no).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in Overall Response Rates","paramValue":"8.99"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.40","spread":"6.40","upperLimit":"15.82","value":"10.4"},{"groupId":"OG001","lowerLimit":"13.85","spread":"13.85","upperLimit":"26.08","value":"19.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"175"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with an objective tumor response of complete response (CR) or partial response (PR) as determined by the IRF using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. Percentages have been rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"NUMBER","populationDescription":"FAS included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received. Overall number analyzed is the number of participants with measurable disease at baseline, as assessed by IRF.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Randomized Phase: Confirmed Objective Response Rate (ORR) as Determined by the IRF","type":"SECONDARY","unitOfMeasure":"percentage of participants"}